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Specific host genes have a  marked influence on virus-induced oncogenesis in 
mice (for review, see reference 1). In many of these models, the complex genetic 
locus (H-2) 1 coding for the major histocompatibility antigens of the mouse plays 
a  key role in determining susceptibility to a  particular neoplasm. In infections 
with Gross leukemia virus (2, 3), Tennant leukemia virus (B/T-L) (4), and some 
strains  of  mammary  tumor  virus  (5,  6),  H-2  o/b  is  strongly  associated  with 
resistance to oncogenesis, whereas H-2  ~/~,  H-2  ~/a, and H-2  ~/~ are associated with 
susceptibility to oncogenesis. 
Friend leukemia virus (FV)  is a  complex of a  defective spleen focus-forming 
virus and a helper lymphoid leukemia virus (7-9). In both young and adult mice 
this complex causes an extremely rapid progressive disease in which the spleen is 
the primary site of growth of neoplastic cells. Foci of tumor cells in the spleen can 
be  detected  7-10  days  after  virus  inoculation  (10),  and  death  in  susceptible 
strains  occurs  within  1-4  mo.  Several  host  genes,  including  the  H-2  locus, 
influence the  virus-host interaction in Friend disease  (1).  H-2  bib  is  associated 
with resistance and H-2  did and H-2  old with susceptibility. In Friend disease, the 
H-2  o/b  resistance  effect  occurs  primarily  after  the  onset  of  virus-induced 
splenomegaly and appears as an increased incidence of recovery from splenomeg- 
aly (11). 
The  mechanism  of  action  of  the  H-2  effects  in  the  virus-host  systems 
mentioned above is unknown. However, the presence within the H-2 complex of a 
region responsible for control of some specific immune responses (Ir region) (12, 
1Abbreviations  used in this paper:  10B, (C57BL/10  x  BALB.B)F~; 10C, (C57BL/10  x  BALB/c) 
FI; BfF-L, BALB Tennant leukemia virus; C3H-MTV, C3H strain of mouse mammary tumor virus; 
FFU,  focus-fbrming units;  FV  Friend  leukemia  virus;  H-2, histocompatibility-2 RFV-1  recovery 
from Friend virus-l; Y10, (C57BL/10  × A.BY)F, ; Y10.A, (B10.A  x  A.BY)F, ; Y10.A(1R),  (B10.A(1R) 
×  A.BY)F,;  Y10.A(2R),  (B10.A(2R)  z  A.BY)F~;  Y10.A(4R),  (B10.A(4R)  x  A.BY)F~;  Y10.A(5R), 
(B10.A(5R)  x  A.BY)F~. 
THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE  • VOLUME 140, 1974  1457 1458  HOST CONTROL  OF RECOVERY FROM  FRIEND LEUKEMIA VIRUS 
13)  suggests that some aspect of control of the host immune system might be 
involved  in  the  association  of H-2  type  with resistance  to  tumorigenesis  (1, 
14-16).  Availability of a  number of recombinants between low (H-2  a) and high 
(H-2  ~)  recovery or resistance alleles (17) prompted us to investigate the role of 
different regions within the H-2 complex in giving rise to a high or low incidence 
of recovery from FV-induced splenomegaly in  mice.  Our results indicate that 
recovery is influenced by a  gene located near or within the D region of the H-2 
complex. The relationship of this gene to other H-2-associated genes influencing 
murine viral oncogenesis is discussed. 
Materials  and Methods 
Animals.  Mouse strains C57BL/10Sn, BALB/cJ, and (BALB/cJ x  A/J)F1 were 
purchased  from  Jackson  Laboratories,  Bar  Harbor,  Maine.  Strains  B10.A, 
B10.A(1R),  B10.A(2R),  B10.A(4R),  B10.A(5R),  and  A.BY/Sn  were  from  the 
colony of Dr.  Jack  Stimpfling,  McLaughlin Research  Institute,  Great  Falls, 
Mont.  Strain BALB.B (H-2  b/b, congenic with BALB/c) was maintained at the 
Rocky Mountain Laboratory from breeder  stock provided by Dr.  Frank Lilly, 
Department of Genetics, Albert Einstein School of Medicine, Bronx, N. Y. 
The  appropriate  congenic  and  recombinant  mice,  bred  on  the  C57BL/10 
genetic background, are homozygous (r/r) at the Fv-2 locus which renders all of 
them  totally resistant  to  Friend  disease  (18, 19). Therefore,  the  experiments 
described herein were carried out with F1 hybrid mice produced by using Fv-2  sis 
mice (BALB.B, BALB/c, and A.BY) as the male parent and the C57BL/10-B10.A 
group of mice as the female parent to obtain offspring susceptible to Friend virus 
(Fv-2SJr).  The following F1 hybrid mice were used: C57BL/10 x  BALB/c, (10C); 
C57BL/10 x  BALB.B, (10B); C57BL/10 x  A.BY, (Y10); B10.A x  A.BY, (Y10.A); 
B10.A(1R)  x  A.BY,  (Y10.A[1R]);  B10.A(2R)  ×  A.BY,  (Y10.A[2R]);  B10.A(4R) 
x  A.BY, (Y10.A[4R]);  B10.A(5R)  x  A.BY, (Y10.A[5R]). All these F1 mice were 
bred at the Rocky Mountain Laboratory. All mice used were homozygous (b/b) at 
the Fv-1  locus  and  therefore were  preferentially sensitive to  B-tropic  murine 
leukemia viruses (19-21). For this reason, the B-tropic strain of Friend virus (22) 
was used in all experiments. 
Virus.  The B-tropic strain of Friend virus was a  gift from Dr.  Frank Lilly. 
This virus was propagated by passage in BALB/cJ or (BALB/cJ x  A/J)F1 mice. 
20%  spleen  homogenates were  made  in  phosphate-buffered saline  containing 
0.002  M  ethylenediamine-tetraacetate (EDTA)  14  days following intravenous 
inoculation  of  7,500  focus-forming  units  (FFU)  (10)  of  virus.  The  crude 
homogenate was clarified by centrifugation at 1,500 rpm for 10 min at 4°C, and 
stored at -100°F in freezing vials. These preparations had titers of 3.0 ±  1.5  x 
106 FFU per ml in BALB/c or (BALB/c x  A/J)F~ mice. 
Virus  Inoculation.  Virus  from  20%  spleen  homogenates  was  thawed,  and 
CaC12 was added to a concentration of 0.002 M to complex the free EDTA. The 
suspension  was  then  reclarified  by  low  speed  centrifugation  as  above.  The 
supernate was diluted in phosphate-buffered balanced salt solution at 0°C, and 
0.5 ml was injected i.v. into each mouse. Assay for spleen focus-forming activity 
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were removed 9 days later, fixed in Bouin's solution, and macroscopic white foci 
visible under the spleen capsule were counted directly. 
Recovery Experiments.  Male  and female mice  11-16  wk of age were used. 
Virus was inoculated as usual, and mice were palpated weekly for splenomegaly 
while under ether anesthesia. Mice were designated as positive for splenomegaly 
by  palpation  only  when  they  had  an  obviously  abnormal  spleen  size.  This 
minimum  level  of detectability was  found to  correspond  to  about  a  fourfold 
increase in spleen weight. Most abnormal spleens were much larger than this and 
weighed 1-3 g, i.e., 10-20-fold larger than normal. Persistence of readily palpable 
splenomegaly was  associated  with  death  of the  animal  within  60-120  days. 
However, mice whose spleen size remained within normal limits survived. 
Statistical Methods.  Analysis of statistical significance of data obtained from 
recovery experiments was done using the X  ~ test for a  2  x  2 contingency table 
(23). 
Results 
In several experiments BALB.B mice (H-2  ~/b) as well as congenic F~ mice of the 
types,  10B  =  C57BL/10  x  BALB.B (H-2  b/b) and  10C  =  C57BL/10  x  BALB/c 
(H-2b/~),  were  inoculated with various doses  of Friend virus  and followed for 
splenomegaly by weekly palpation. The results when 30  FFU and 300  FFU of 
virus were inoculated are shown in Figs.  1 and 2.  At the lower dose the peak 
incidence of splenomegaly in the 10B mice was slightly lower than in the other 
strains.  However,  the  most  striking  differences  occurred  20-40  days  after 
inoculation when  a  large  percentage  of the  10B  mice  began  recovering from 
splenomegaly, whereas few or none of the 10C  and BALB.B mice did so. This 
trend was continued throughout the observation period of 60-90 days. By 3 mo 
almost  all  mice  with  persistent  splenomegaly were  dead,  and  those  without 
splenomegaly  appeared  healthy  and  normal.  In  most  cases  recovery  was 
extremely rapid  with  spleen  size  regressing to within normal  limits  over the 
course  of only 1  wk.  At day 50  postinoculation the  reduction in  incidence of 
splenomegaly in  10B  mice was  highly significant (P  <  0.005)  compared with 
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FzG.  1.  Incidence of Friend disease as expressed by death (  .... ) and splenomegaly or death 
(  ) following intravenous inoculation of 30 FFU of FV. Data from three experiments. ~, 
BALB.B (H-2~/°),  13 mice; Q,  10B (H-2°/o),  26 mice; O,  10C  (H-2b/~), 28 mice. 1460  HOST  CONTROL  OF  RECOVERY  FROM  FRIEND  LEUKEMIA  VIRUS 
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FIG.  2.  Incidence  of Friend  disease  as expressed  by death  [ .... )  and sp|enomegaly  or death 
(  ) following intravenous inoculation  of 300 FFU of FV.  Data from three experiments. ~, 
BALB.B  (H-2b!~),  12 mice; O,  10B (H-2~/b), 23 mice;  C),  10C  (H-2b d),  10 mice. 
either 10C or BALB.B mice for both doses shown (Figs. 1 and 2). In congenic F1 
mice, H-2  bj~ is associated with a high incidence of recovery from Friend disease 
compared with H-2  bid. Interestingly BALB.B mice, which are also H-2  bib, never 
recovered  at  the  doses  studied.  Initial  FV  inoculation  dose  also  influenced 
incidence of recovery from splenomegaly within a  given strain. Nearly 100% of 
10B mice recovered when 30 FFU of FV were inoculated, but only 48% recovered 
when 300 FFU were inoculated. At doses of 3,000 FFU and 30,000 FFU, only rare 
recovery was noted in this hybrid (Table I). 
Response  of H-2 Recombinant  Lines.  Several experiments were carried out 
with mice of the prototype hybrids, Y10  (H-2  ~/~) and Y10.A  (H-2  b/a) as well as 
H-2  recombinant  hybrids,  Y10.A(1R),  Y10.A(2R),  Y10.A(4R)  and  Y10.A(5R), 
and the H-2  ~jo parent, A.BY. When 300 FFU of virus were given, 100% of mice of 
both Y10  and Y10.A  types recovered from splenomegaly (Table I). Results for 
3,000  FFU and 30,000  FFU are shown in Figs. 3 and 4. The peak incidence of 
splenomegaly was observed at 9-15 days postinoculation, and at the highest virus 
dose  (30,000  FFU)  there  was  nearly a  100% incidence of splenomegaly in all 
hybrids. At 3,000  FFU peak incidence of splenomegaly was significantly (P  < 
0.05) reduced in Y10 mice compared to Y10.A mice. However, as demonstrated in 
the BALB hybrids, more dramatic differences occurred among the various Y10 
hybrids at  20-30  days postvirus  when a  large  percentage  of Y10,  Y10.A(1R), 
Y10.A(2R),  and Y10.A(4R)  mice began to recover from splenomegaly, whereas 
only an occasional Y10.A  or Y10.A(5R)  mouse did so. This trend continued for 
the duration of the experimental observation period. In all hybrids studied there 
was  a  small  percentage  (2-5%)  of individual mice  whose  splenomegaly tran- 
siently regressed  only to  be  terminated  by  a  relapse  with  splenomegaly and 
death. A summary of the results is given in Fig. 5.  All high recovery mice are 
homozygous (b/b) at the D region of the H-2 complex. This is the only portion of 
the complex at which they are genotypically identical. Furthermore, both low 
recovery hybrids are heterozygous (a/b)  at this region. This would indicate that 
the portion of the H-2 complex responsible for the high incidence of recovery is 
located near or within the H-2D  region, i.e., to the right of the recombination 
point(s)  in  the  1R  and  2R  mice.  Statistical  analysis  was  done  for  day  50 
postinoculation when all populations appeared stable with regard to splenomeg- BRUCE  CHESEBRO,  KATHY  WEHRLY,  AND JACK  STIMPFLING 
TABLE  I 
Influence  o/Virus Dose on Recovery 
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Virus dose  Mice:  10B  10C  BALB/B  Y10  Y10.A  A.BY 
(spleen  H-2:  b/b  b/d  b/b  b/b  b/a  b/b 
FFU) 
30  2/26*  22/28  13/13  NT  NT  NT 
300  11/23  10/10  12/12  0/15  0/17  3/3 
3,000  9/10  NT  NT  4/28  14/20  3/3 
30,000  4/5  NT  NT  9/46  59/70  11/13 
* Number  of  mice  with  splenomegaly  or  dead/total  number  injected.  Data  for  day  50  postvirus 
inoculation. 
NT, not tested. 
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FIG.  3.  Incidence  of  Friend  disease  as  expressed  by  splenomegaly  or  death  following 
intravenous inoculation of 3,000 FFU of FV. Data from two experiments. Y10, 28 mice; Y10.A, 
20 mice; Y10.A(4R),  23 mice; Y10.A(5R),  21 mice. 
aly. There are highly significant differences (P  <  0.001) between the strains of 
the  low  and  high  recovery groups;  however,  within  each  group  there  are  no 
significant differences. 
Several additional facts emerged from these experiments. First, as was seen in 
BALB  hybrids,  the  magnitude  of the  recovery effect in  any given strain  was 
dependent  on  initial  FV  dose.  In  this  regard  the  BALB  hybrids  are  about 
1,000-fold more sensitive than the A.BY hybrids. Second, the H-2  ~/b (nonhybrid) 
A.BY parental strain did not exhibit the recovery effect at all. This is similar to 
what  was  observed  with  BALB.B  (H-2  bib)  mice.  Thus  is  it  clear  that  major 
genetic factors necessary for expression of the H-2 associated recovery effect are 
manifest in the F1 hybrids but not in the BALB.B or A.BY parents. 
Spleen Focus Assay.  In order to examine possible differences in virus-host 
interaction in  the  FV  system,  some  of the  mouse strains  studied  in  recovery 
experiments were compared for their ability to form FV-induced spleen foci. The 
results,  shown  in  Table  II,  indicate  that  no  significant  differences in  focus 
formation occurred among any of the mouse strains studied when inoculated with 
a  standard FV preparation. A.BY mice were not included as they do not make 
countable foci with the virus preparation used. 1462  HOST CONTROL OF RECOVERY FROM FRIEND LEUKEMIA VIRUS 
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Fro.  4.  Incidence  of  Friend  disease  as  expressed  by  splenomegaly  or  death  following 
intravenous inoculation  of 30,000 FFU of FV. Data from five experiments. Y10, 46 mice; Y10.A, 
70 mice; Y10.A(IR}, 15 mice; Y10.A{2R), 31 mice; Y10.A(4R), 62 mice; Y10.A(5R), 44 mice. 
F1 HYBRID 
YIO 
H-2  COMPLEX 
Ir- IgG 
K  Ir- /  Ir- IgA  Ss-SIp  D  Recovery from 
FV Induced Siolenome~aly 
I  !  !  !  "  " 
High 
YIO. A[IR]  High 
Y10. A[2RI  High 
YIO. A[4R]  High 
Y10.A[SR]  Low 
YIO. A  Low 
J  J:H-2 a 
Fro.  5.  Relationship between  recovery from splenomegaly  and genotype  at known regions 
within the H-2 complex. Gene influencing  recovery from FV induced splenomegaly  (RFV-1) 
maps with the D region of the H-2 complex. H-2 data adapted from references 13 and 23. 
Discussion 
Early studies by Lilly (11)  on the  influence of H-2 type on Friend disease were 
done on a backcross population in which many genes were segregating simultane- 
ously.  This  work  suggested  a  strong  association  between  H-2  type  and  both 
incidence and  recovery  in Friend disease.  Comparing congenic mice,  BALB/c BRUCE  CHESEBRO,  KATHY  WEHRLY,  AND JACK  STIMPFLING 
TABLE  II 
FV Spleen Focus Formation in  Various Mouse Strains 
FV titer 
Mice  (FFU/ml x  10  *) ±  SD 
BALB/c  10.5 ± 4.4 
BALB.B  12.0 ± 14.2 
10B  8.1 ± 5.5 
10C  12.5 ± 4.6 
Y10  7.1 ± 1.8 
Y10.A  8.0 ± 2.8 
Various twofold dilutions were made of a standard FV stock preparation 
and 0.5 ml was injected intravenously into the mice shown. Spleen foci 
were counted on day 9. 9-12 female mice were used from each strain. 
1463 
(H-2  ~/a)  and  BALB.B  (H-2O/b),  it  was  found  that  these  strains  differ  in 
susceptibility to induction of splenomegaly by a  virus-dose factor of 10 or more 
(25).  The  present experiments with  congenic F1  mice  confirm the  observation 
that  the  H-2  locus  itself is  responsible for  the  differences in the  incidence of 
recovery  seen  previously  in  backcross  populations.  Furthermore,  the  results 
obtained using mice with H-2 recombinations indicate that the H-2-associated 
gene involved in recovery from Friend disease is located in or near the D  region of 
the  H-2  complex  (Fig.  5).  We  have  tentatively designated  this  gene,  RFV-1 
(recovery from Friend virus). 
Previous studies (6) on the C3H strain of mammary tumor virus (C3H/MTV) suggest a 
similar  association  between  susceptibility to  oncogenesis and  the  D  end  of  the  H-2 
complex. The susceptibility of H-2  ~  mice (B10.BR)  is intermediate (50%)  and that of 
H-2  ~/~ mice (B10.D2) is high (100%).  H-2  ~/a mice (B10.A) are identical with H-2  ~/d mice. 
Since H-2  ~ appears to be a recombinant chromosome containing K  and Ir alleles of H-2  ~ 
and Ss-Slp and D alleles of H-2  d, the high susceptibility shared by H-2  ~/d and H-2  ~/a mice 
must be derived from the Ss-Slp  or D  regions of the H-2 complex. Similar results have 
been observed studying B/T-L virus leukemogenesis in these same strains of mice (4). As 
with Friend virus, highest resistance to both B/T-L and C3H-MTV is associated with the 
H-2  b allele. Whether the gene(s) involved in these two systems is identical with RFV-I is 
unknown. 
Slightly different findings were observed in studies of the H-2 associated Rgv-1  gene, 
which  influences resistance to  Gross virus leukemogenesis (2).  H-2  ~ is  again the  most 
resistant allele, and H-2% H-2  k, and H-2  ~ are susceptible. However, in studies of mice with 
recombinations within the H-2 complex (strains: HTH, HTI, HTG) resistance to Gross 
virus appeared to be associated with the K end of the H-2 complex (3). In other studies of 
spontaneous leukemia observed in a backcross population, [AKR x  (BALB/c x  AKR)F1], 
a significantly higher incidence of leukemia was associated with H-2  ~  mice compared to 
H-2  ~  mice (26).  It is not known whether this effect is due to the Rgv-1  gene. However, 
this result is the opposite of what one would predict based on results with Bfr-L virus and 
MTV  where  H-2  ~ is  a  more  resistant allele than H-2  ~.  These data  plus those  on H-2 
recombinants could be interpreted as indicating that Rgv-1 is not identical with RFV-1 or 
with the genes which influence the B/T-L and C3H-MTV systems. 1464  HOST  CONTROL  OF  RECOVERY FROM  FRIEND  LEUKEMIA VIRUS 
Since the discovery of the location of the Ir region within the H-2 complex (12, 
13), an association of major histocompatibility antigen types with various disease 
processes including  "autoimmune"  phenomena and neoplasia in both mice and 
humans has been noted  (1,  14-16,  27,  28).  Genes which control specific immune 
responses could be the common mediators of these effects. A possible example of 
this is the recently described X.1 system of leukemia-associated transplantation 
antigens present on cell surfaces and virion envelopes {29). In this model, ability 
to  form  cytotoxic  antitumor  antibody  was found  to  be  linked  to  the  K  and  Ir 
regions of the H-2 complex. Similarly in Friend disease, a  genetically controlled 
specific  immune  response  could  account  for  the  recovery  phenomenon  seen. 
However, because the gene involved maps with the D  region and not with the Ir 
region as now defined, it could have a mechanism of action quite independent of 
the Ir gene system. Since the D  region is known to be important in determining 
transplantation  antigens present on cell surfaces, the RFV-1 gene might exert its 
influence  via expression  of tumor-specific cell surface antigens  (25).  Of course, 
the  alternative exists that another/r-like region could be located near or within 
the D  region of the H-2 complex. 
Other  possible aspects of virus-host interaction  must also be considered  in  thinking 
about  the  role  of the  RFV-I  gene.  Viral  infectivity and  growth  kinetics  could  have a 
profound influence on ultimate recovery from splenomegaly. Our data indicate that the 
various strains studied do not differ significantly in the formation of spleen foci induced by 
FV (Table II). This suggests that there are similar numbers of target cells for malignant 
transformation  in  each  of the  strains  and  that  RFV-1  does  not  exert  its influence  on 
recovery via  differences  in  the  number  of cells  first  transformed  by the  initial  virus 
inoculum.  This  would  appear  to  be  a  reasonable  interpretation  for the  10C  and  10B 
hybrids, since the virus dose used in the most significant recovery experiments (30 FFU) is 
similar to the  amount inoculated  in the  various dilutions of the spleen focus titration. 
Thus it has been directly determined that 9 days after injection of 30 FFU of virus, both 
10B and 10C mice have approximately 30 foci per spleen. However, if these mice are not 
killed but instead observed for a longer period, the 10B mice recover from splenomegaly 
whereas the 10C mice do not. With the A.BY hybrids this argument is less straightforward 
since the dose used in most recovery experiments is 1,000-fold  higher than that used in a 
focus assay,  and  the  effects of high  virus  multiplicity  cannot  be  determined  from the 
dilution procedure used in titrating FFU. 
In considering possible RFV-1 gene functions an additional observation which 
must be accounted for is the striking influence of the initial dose of FV inoculated 
on the  incidence  of recovery several weeks later within  any particular  strain  of 
mice.  A  higher  dose  might  lead  to  an  increase  in  total body virus load  and/or 
tumor cell burden. Additionally the higher input of virus might be more effective 
in  crucial  early  immunosuppression  of host  defenses.  Our  current  preliminary 
studies 2 comparing antiviral and antitumor antibody responses of Y10 and Y10.A 
mice following FV  inoculation  tend  to indicate  that  both hybrid types develop 
equally potent antiviral  neutralizing  antibody titers  coincident  with the  disap- 
2  Chesebro, B. and K. Wehrly. 1974. Unpublished  observations. BRUCE  CHESEBRO,  KATHY WEHRLY,  AND JACK STIMPFLING  1465 
pearance of free virus from plasma and a decrease in infectious virus recoverable 
from  the  spleen.  In addition,  there  appears to be  no correlation of presence of 
cytotoxic antitumor antibodies with recovery in either hybrid. In summary, we 
have no evidence indicating any differences in the immune response of these two 
hybrids. Studies are in progress to attempt to define and compare cell-mediated 
antitumor immune phenomena and viral growth kinetics in these mice. 
The  striking  differences  between  H-2  ojo  parental  mice  (BALB.B and  A.BY) 
and  H-2~/°F1  mice  (Y10  and  10B)  in  recovery  from  Friend  disease  strongly 
emphasize the importance of other non-H-2 genetic factors that are essential for 
clear expression of the H-2-associated recovery effect. These two groups of mice 
do differ at another gene, Fv-2, known to influence spleen focus formation by FV 
(18,  19).  BALB.B  and  A.BY  are  Fv-2  sj8  and  the  hybrids  are  Fv-28jr,  having 
obtained one resistant allele from the parent of C57BL background. Although it 
has  been  shown  previously  that  sensitivity(s)  is  dominant  at  this  locus,  the 
possibility remains  that  there  are  quantitative  differences between Fv-28~  and 
Fv-2  "jr  mice which become more apparent in the presence of the  high recovery 
H-2  bib  genotype.  The  experiments  of Dawson  and  Fieldsteel  (30)  on  chronic 
remittant  Friend  disease  in  (C57BL/6  ×  DBA/2)F1  mice  provide  additional 
evidence for enhanced recovery in C57BL hybrids. These authors concluded that 
the  most important factors influencing the incidence and duration of remission 
were age of the mice at inoculation and size of the inoculum. Remission occurred 
in mice inoculated at 8 wk of age or older. In this work no attempt was made to 
identify  the  genes  responsible  for  the  observed  effects;  however,  the  general 
characteristics of the remissions were similar to the recoveries seen in the present 
studies.  We noted a  similar  age dependence for RFV-l-mediated  recovery, and 
therefore used mice 11-16 wk old in all experiments. In a  few instances we have 
followed mice  as  long as 8  mo and only very rarely noted relapse  of neoplastic 
disease and recurrent splenomegaly in this system. 
Existence of other non-H-2 genetically controlled factors influencing recovery in Friend 
disease  is  evident  when  the  dose  responses  of BALB hybrids  and  A.BY  hybrids  are 
compared (Table II). At a dose of 30,000 FFU, A.BY hybrids of different H-2 types are 
distinguishable,  but a virus dose of only 30 FFU is necessary to obtain a similar recovery 
pattern with BALB hybrids. At 300 FFU all A.BY hybrids recover regardless of H-2 type, 
whereas only half of the  10B hybrids (H-2  blo) and none of the  10C hybrids (H-2  hI") do. 
Therefore,  based  on  incidence  of recovery,  BALB  hybrids  are  about  1,000-fold  more 
sensitive than A.BY hybrids to a given dose of virus. This may in fact be related to the 
lower sensitivity of A mice compared to BALB/c in both spleen focus formation by FV (31) 
and leukemogenesis induced by Gross  virus (3).  The resistance to Gross virus seen in A 
mice  is  also  seen  in  (BALB/c  ×  A)F1 mice.  Therefore  this  resistance  appears  to  be 
genetically dominant, and could be a factor in our A.BY hybrid mice. On the other hand, 
the effect on resistance to FV focus induction is recessive i.e.,  (BALB/c x  A)F1 mice are 
similar  to  BALB/c  mice ~ and  give  about  10-fold  more  foci  than  A  mice  following 
inoculation with a given virus preparation (31). Our data on spleen focus formation (Table 
II) indicate no significant differences between BALB and A.BY hybrids in this assay. Thus 
it  would  appear  likely  that  the  recessive  host genetic  factors influencing spleen  focus 
formation  in  A  strain  mice  are  different  from  the  factors  involved  in  the  1,000-fold 
differences between BALB and A.BY hybrids seen in FV recovery experiments. 1466  HOST  CONTROL  OF  RECOVERY  FROM  FRIEND  LEUKEMIA VIRUS 
Study  of  specific  host  genes  which  influence  murine  viral  leukemogenesis 
provides  a  powerful  tool  for  examining  detailed  aspects  of  host-virus-tumor 
interactions.  The  present  experiments  have  defined  the  genetic  linkage  of one 
gene  which  is  important  in  influencing  host  recovery from  Friend  disease.  In 
addition  the  data suggests the  existence of two other host genes which strongly 
influence  the recovery process. Through isolation of individual  genes on similar 
genetic backgrounds analysis of the mechanisms of action of these genes will be 
greatly  facilitated.  Understanding  of  these  mechanisms  should  be  of  major 
interest to the  general area of host control of neoplasia. 
Summary 
The influence of the major mouse histocompatibility gene complex (H-2) on the 
response  of  mice  to  Friend  leukemia  virus  was  studied  in  F1  congenic  mice 
differing only at genes within the H-2 complex. F1 mice which were H-2  b/o had a 
high incidence of recovery from splenomegaly compared to H-2  ~/d or H-2  b~a mice. 
In mice with recombinations within the H-2 complex a gene (designated RFV-I), 
responsible for the Friend virus recovery effect, was found to map near or within 
the  D  region  of serologically  detectable  transplantation  antigens.  Because  the 
incidence of recovery was much higher in F1 H-2  ~b mice than in parental H-2  ~/b 
mice,  other  non-H-2  host  genetic  factors  also  appear  to  be  important  to 
expression of recovery in H-2  b/~ F~ mice. The mechanisms of action of these genes 
remain unknown. 
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